Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Flonase DTC Ads Highlight Formulary Status Versus Antihistamines

  • News

Executive Summary

GlaxoSmithKline's direct-to-consumer ads for Flonase emphasize that "99% of prescription plans" cover the allergy nasal spray

You may also be interested in...



Allegra DTC Ads Include Comparative Claims Against Zyrtec, OTCs

Aventis is running direct-to-consumer television ads for Allegra highlighting its non-sedating profile in comparison to other prescription and over-the-counter antihistamines

Allegra DTC Ads Include Comparative Claims Against Zyrtec, OTCs

Aventis is running direct-to-consumer television ads for Allegra highlighting its non-sedating profile in comparison to other prescription and over-the-counter antihistamines

Flonase, Zaditor DTC Ads Cited By FDA; Both Allergy Campaigns Are Over

FDA is directing GlaxoSmithKline and Novartis to revise direct-to-consumer ads for allergy products attempting to capitalize on the changes in the market following the OTC switch of Claritin

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS041433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By